# Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)

> **NCT00811031** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Taxotere
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00811031
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00811031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00811031, "Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00811031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*